German Teenager's Cancer Remission Highlights Innovative Treatment
A 16-year-old boy from near Darmstadt, Germany, successfully battled a recurring cancerous tumor above his left eye through an experimental treatment at the KiTZ Heidelberg, involving testing multiple drugs on mini-tumors derived from his tissue sample, resulting in remission.
German Teenager's Cancer Remission Highlights Innovative Treatment
A 16-year-old boy from near Darmstadt, Germany, successfully battled a recurring cancerous tumor above his left eye through an experimental treatment at the KiTZ Heidelberg, involving testing multiple drugs on mini-tumors derived from his tissue sample, resulting in remission.
Progress
36% Bias Score
AI-designed treatment shows promise for snakebite envenomation
A team led by Dr. Susana Vázquez used AI to create a new treatment for snakebite envenomation, a neglected tropical disease causing over 100,000 deaths annually; the treatment showed 100% survival rates in mice trials and is published in Nature.
AI-designed treatment shows promise for snakebite envenomation
A team led by Dr. Susana Vázquez used AI to create a new treatment for snakebite envenomation, a neglected tropical disease causing over 100,000 deaths annually; the treatment showed 100% survival rates in mice trials and is published in Nature.
Progress
52% Bias Score
Italian Researcher's Open-Source AI Rivals DeepMind's AlphaFold3
Gabriele Corso, a 25-year-old Italian researcher at MIT, developed Boltz-1, an open-source AI model for analyzing molecular interactions with accuracy matching DeepMind's AlphaFold3, revolutionizing drug discovery by making advanced AI accessible to researchers worldwide.
Italian Researcher's Open-Source AI Rivals DeepMind's AlphaFold3
Gabriele Corso, a 25-year-old Italian researcher at MIT, developed Boltz-1, an open-source AI model for analyzing molecular interactions with accuracy matching DeepMind's AlphaFold3, revolutionizing drug discovery by making advanced AI accessible to researchers worldwide.
Progress
40% Bias Score
AI-Developed Drug Shows Promise in Cardiovascular Disease Treatment
Algorae Pharmaceuticals' AI-168 drug combination, partly involving cannabidiol, has shown significant promise in pre-clinical in-vitro studies to improve on existing treatments for cardiovascular disease, outperforming beta-blockers in three cell line models and leading to an international patent ap...
AI-Developed Drug Shows Promise in Cardiovascular Disease Treatment
Algorae Pharmaceuticals' AI-168 drug combination, partly involving cannabidiol, has shown significant promise in pre-clinical in-vitro studies to improve on existing treatments for cardiovascular disease, outperforming beta-blockers in three cell line models and leading to an international patent ap...
Progress
56% Bias Score
Manas AI: AI-Powered Drug Discovery Startup Launches with $24.6 Million in Seed Funding
Reid Hoffman and Dr. Siddhartha Mukherjee launched Manas AI, a $24.6 million AI-powered drug discovery startup targeting aggressive cancers, aiming to significantly reduce development time and costs using proprietary chemical libraries and AI filters.
Manas AI: AI-Powered Drug Discovery Startup Launches with $24.6 Million in Seed Funding
Reid Hoffman and Dr. Siddhartha Mukherjee launched Manas AI, a $24.6 million AI-powered drug discovery startup targeting aggressive cancers, aiming to significantly reduce development time and costs using proprietary chemical libraries and AI filters.
Progress
44% Bias Score
AI Startup Collate Secures \$30 Million, Aims to Automate Life Sciences Documentation
Surbhi Sarna, after selling her previous startup nVision Medical for \$275 million, launched Collate, an AI-powered life sciences documentation automation startup, securing \$30 million in seed funding and a valuation exceeding \$100 million.
AI Startup Collate Secures \$30 Million, Aims to Automate Life Sciences Documentation
Surbhi Sarna, after selling her previous startup nVision Medical for \$275 million, launched Collate, an AI-powered life sciences documentation automation startup, securing \$30 million in seed funding and a valuation exceeding \$100 million.
Progress
48% Bias Score
€400,000 Grant Funds Multi-Omic Leukemia Therapy Research at University of Parma
The University of Parma's Translational Hematology and Chemogenomics group received a €400,000 grant to develop personalized therapies for high-risk acute leukemias using a multi-omic model integrating genomic, proteomic, and metabolic data, led by Giovanni Roti in collaboration with Alessio Lodola.
€400,000 Grant Funds Multi-Omic Leukemia Therapy Research at University of Parma
The University of Parma's Translational Hematology and Chemogenomics group received a €400,000 grant to develop personalized therapies for high-risk acute leukemias using a multi-omic model integrating genomic, proteomic, and metabolic data, led by Giovanni Roti in collaboration with Alessio Lodola.
Progress
8% Bias Score